Zobrazeno 1 - 10
of 418
pro vyhledávání: '"major molecular response"'
Autor:
T. N. Aleksandrova, I. I. Mulina, A. S. Lyamkina, A. A. Studenikina, N. A. Varaksin, E. S. Mikhaylova, T. I. Pospelova, A. I. Autenshlyus
Publikováno v:
Медицинская иммунология, Vol 26, Iss 2, Pp 329-336 (2024)
Resistance to tyrosine kinase inhibitors (TKIs) is currently an important clinical problem in the management of patients with chronic myeloid leukemia (CML). Recent studies suggested that aberrant cytokine secretion may be among the BCR/ABL-independe
Externí odkaz:
https://doaj.org/article/5aeabf4908d4476990d83e56d7d6d063
Autor:
Junichiro Yuda, Noriko Doki, Hiroshi Matsuoka, Takafumi Yokota, Akihiro Tomita, Naoto Takahashi, Itaru Matsumura, Kohmei Kubo, Tatsunori Goto, Keita Kirito, Akio Maki, Makoto Aoki, Alex Allepuz, Yosuke Minami
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2990-2998 (2023)
Abstract Asciminib, a first‐in‐class, allosteric inhibitor of BCR‐ABL1 that acts by STAMP (Specifically Targeting the ABL Myristoyl Pocket), is a novel therapeutic option for patients with chronic myeloid leukemia (CML). In the global, phase 3,
Externí odkaz:
https://doaj.org/article/f3495850c1564a0f97780c72bafe4f5e
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Reema Singh, Jyotsna Kapoor, Rayaz Ahmed, Pallavi Mehta, Vishvdeep Khushoo, Pragya Agrawal, Dinesh Bhurani, Narendra Agrawal
Publikováno v:
South Asian Journal of Cancer, Vol 10, Iss 04, Pp 246-250 (2021)
Context Nilotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML). Aims We aim to evaluate the responses and safety of upfront Nilotinib therapy in Indian CML patients. Setting and Des
Externí odkaz:
https://doaj.org/article/f2f652b4c4ca41589504fa425f5e33b7
Publikováno v:
Терапевтический архив, Vol 92, Iss 7, Pp 90-94 (2020)
Therapy with tyrosine kinase inhibitors (TKI) allows to achieve a deep molecular response in 6070% of patients with chronic myeloid leukemia (CML). According to the current guidelines CML patients receive a long-term treatment with TKI in standard do
Externí odkaz:
https://doaj.org/article/4612f90d3bd9452f95daf6025e11e77c
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 2, Pp 534-537 (2020)
Chronic myelogenous leukemia (CML) is a hematopoietic disorder caused by the BCR/ABL gene or Philadelphia chromosome. The first Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor for treatment of CML was imatinib in 2001. Since the
Externí odkaz:
https://doaj.org/article/c9e85d8d727d45db9753bbe96a56efed
Autor:
A. S. Lyamkina, L. M. Maslova, O. V. Naumenko, E. V. Melnichenko, Yu. N. Obgolts, A. B. Loginova, E. V. Daragan, I. N. Nechunaeva, E. V. Vorontsova, L. A. Shpagina, A. V. Yudanov, K. V. Khalzov, T. I. Pospelova
Publikováno v:
Сибирский научный медицинский журнал, Vol 40, Iss 1, Pp 31-38 (2020)
The incidence of chronic myeloid leukemia from 2004 to 2018 amounted to 0.63 per 100 000 people per year. The prevalence of chronic myeloid leukemia over the past 15 years has increased from 1.88 to 7.02 case per 100 000 people. We have analyzed the
Externí odkaz:
https://doaj.org/article/a7831e47dad64e70b11d786e83a6b3d8
Autor:
Sudha Sazawal, Sunita Chhikara, Kanwaljeet Singh, Rekha Chaubey, Manoranjan Mahapatra, Tulika Seth, Renu Saxena
Publikováno v:
Indian Journal of Pathology and Microbiology, Vol 62, Iss 2, Pp 256-260 (2019)
Background: Philadelphia chromosome (Ph): Hallmark of CML is caused by reciprocal translocation between chromosomes 9 and 22 resulting in BCR-ABL fusion protein. Most commonly associated breakpoint with CML is M-bcr in exon 13 or exon 14, producing s
Externí odkaz:
https://doaj.org/article/17707d6c67a941afb586eeee5cb32066
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Treatment of chronic myeloid leukemia (CML) has evolved dramatically in recent years. In this regard, the introduction of second-generation tyrosine kinase inhibitors (TKI) has revolutionized therapeutic goals, and it is now desirable to obtain treat
Externí odkaz:
https://doaj.org/article/b8a518558c3442d1939675013bb547e9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.